In 2004, GTC licensed its IP to Nexia for the biodefense product, Protexia (#msg-4107224). Protexia is now owned by PharmAthene (who since merged with SIGA: #msg-11540838).
GTC could some day realize a small royalty stream from this.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.